Addition to Siegfried Group’s Executive Committee

Since joining Siegfried in January 2021, he has already been responsible as Multi-Site Head Drug Products for the two Spanish sites Barberà del Vallès and El Masnou as well as for the Irvine site. He will now also be responsible for the sites in Hameln (Germany) and Hal Far (Malta). Marcel Imwinkelried takes over this function from CEO Wolfgang Wienand, who has led the Drug Products operations ad interim since January 1, 2021. At the beginning of the year, in the course of the acquisition of the two pharmaceutical production sites from Novartis in Spain, Siegfried divided its Technical Operations into two areas of responsibility, Drug Substances and Drug Products, due to the new size of the company. With the appointment of Irene Wosgien as Chief Operating Officer Drug Substances as of January 2021 and the appointment of Marcel Imwinkelried as Chief Operating Officer Drug Products, this process has now been completed.

Marcel Imwinkelried graduated in mechanical engineering from the Lucerne University of Applied Sciences and holds a degree in business administration from the University of St. Gallen. After completing his studies and starting his career at a chemical company, he joined Novartis in 2005, where he held various management positions with increasing responsibility and, from 2018, was appointed Global Head Technical Operations Solids.

Dr. Wolfgang Wienand, CEO of Siegfried: “With Marcel Imwinkelried, we have gained a proven expert in the field of Drug Products with extensive experience in managing global production networks for our company and now for the Executive Committee. During the integration of the two Spanish sites since the beginning of the year, he has already proven that he can make valuable contributions to Siegfried’s future success. Now I look forward to continuing to work with Marcel Imwinkelried and wish him much success and joy in his challenging new role.”

About Siegfried

The Siegfried Group is a global life sciences company with sites in Switzerland, Germany, Spain (from 1.1.2021), France, Malta, the USA and China. In 2020, the company achieved sales of 845.1 million Swiss francs and employed on 31.12.2020 about 2’500 people at nine sites on three continents. Following the acquisition of two sites in Spain as per 01.01.2021, this number rose to approximately 3’500 employees. Siegfried Holding AG is publicly listed on SIX Swiss Exchange (SIX: SFZN).

Siegfried is active in manufacturing pharmaceutical APIs (and their intermediates) as well as drug products (tablets, capsules, sterile vials, ampoules, cartridges and ointments) for the pharmaceutical industry and provides development services.

Cautionary Statements Regarding Forward-Looking Statements

This media release includes statements concerning the future. They are based on assumptions and expectations that may prove to be wrong. They should be considered with due caution as, by definition, they contain known and unknown risks, insecurities and other factors which could result in a difference in the actual results, financial situation, developments or the success of Siegfried Holding AG or Siegfried Group from the explicit or implicit assumptions made in these statements.